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Abstract
Introduction: The HOXB13:IL17BR index has been identified to predict clinical outcome in the setting of adjuvant
tamoxifen monotherapy of breast cancer. Further studies have shown that HOXB13 in particular can indicate
benefit of prolonged tamoxifen treatment. Patients with high-expressing tumors did not benefit from prolonged
treatment, suggesting that HOXB13 might be involved in tamoxifen resistance. No studies have been made
regarding the HOXB13 protein levels in breast cancer. The aim of our study was to investigate whether tamoxifen
benefit can be correlated to different levels of HOXB13 protein expression.
Methods: We used immunohistochemistry to analyze protein levels of HOXB13 in tumor samples from 912
postmenopausal node-negative breast cancer patients randomized to adjuvant tamoxifen therapy or no endocrine
treatment.
Results: Tamoxifen-treated patients with estrogen receptor-positive tumors expressing none or low levels of
HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival (DRFS) (hazard ratio
= 0.38, 95% confidence interval = 0.23 to 0.60, P = 0.000048). However, for patients with a high or intermediate
HOXB13 tumor expression, tamoxifen did not prolong the DRFS compared with the untreated patients (hazard
ratio = 0.88, 95% confidence interval = 0.47 to 1.65, P = 0.69). Interaction between HOXB13 expression and benefit
from tamoxifen was statistically significant for DRFS (P = 0.035). No prognostic value could be ascribed to HOXB13
among systemically untreated patients.
Conclusions: A high HOXB13 expression was associated with decreased benefit from tamoxifen, which indicates
that HOXB13 protein level may be used as a predictive marker for tamoxifen treatment.
Introduction
There have been several recent studies aimed at disco-
vering novel biomarkers and gene signatures usable for
predicting risk of recurrence and response to endocrine
therapy of breast cancer [1-4]. With the development of
robust, reliable genetic markers for this purpose, it
would be possible at an early stage to predict which
patients would benefit from alternative hormonal thera-
pies. Resulting gene signatures, based on genome-wide
microarray analyses, are often very comprehensive and
comprise a large number of genes. However, Ma and
colleagues were able to show that their gene expression
profiles of hormone receptor-positive invasive breast
tumors could be reduced into a simple two-gene ratio
predictive of tumor relapse in the setting of adjuvant
tamoxifen monotherapy [5]. Subsequent studies of the
HOXB13:IL17BR index have proven its significance in
predicting risk of breast cancer recurrence and tamoxi-
fen response [6-9].
Our previous study of the HOXB13:IL17BR expression
ratio indicated that the two genes individually could
function as separate prognostic and treatment predictive
markers in breast cancer [8]. Expression of IL17BR was
inversely correlated to a number of factors related to a
poor prognosis, whereas HOXB13 could predict recur-
rence in tamoxifen-treated patients. Patients with
tumors expressing a high level of HOXB13 were more
likely to be unresponsive to the therapy, suggesting that
this gene is involved in tamoxifen resistance.
HOXB13 is a member of the homeobox gene family, a
group of genes encoding transcriptional regulators of
cell growth and differentiation, predominantly during
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the homeobox genes in these events, but the role of
HOXB13 in breast cancer and endocrine resistance is
only beginning to be elucidated. The expression of
HOXB13 is known to be upregulated in breast cancer
cells compared with normal breast epithelium [5,10] and
it has also been shown that HOXB13 is an estrogen-
regulated gene negatively correlated to estrogen receptor
(ER) status [11,12]. Wang and colleagues suggest that a
high HOXB13:IL17BR index may indicate impaired ER
signaling, which is known to predict resistance to
tamoxifen [12].
To our knowledge, there are no studies investigating the
HOXB13 protein levels in breast cancer and its signifi-
cance in predicting outcome after tamoxifen treatment. In
the present study, we used immunohistochemistry to
analyze the protein expression of HOXB13 in tumor sam-
ples from 912 postmenopausal breast cancer patients. The
patients were participants in a randomized trial analyzing
the benefit from adjuvant treatment with tamoxifen,
which enabled us to investigate the treatment predictive
value of HOXB13.
Materials and methods
Patients
We analyzed tumor tissue from patients enrolled in a
randomized tamoxifen trial comprising a total of 1,780
low-risk breast cancer patients, conducted in the Stock-
holm region in Sweden from 1976 to 1990 [13]. All
patients were postmenopausal at the time of diagnosis,
presented a tumor size ≤30 mm, and displayed no nodal
involvement (N0). The patients were randomized to
2 years of endocrine treatment with tamoxifen (40 mg
daily) or no adjuvant endocrine treatment. In 1983 a
new trial was initiated; recurrence-free patients were,
after 2 years of tamoxifen treatment, randomized to
3 years more of tamoxifen or no further therapy.
Tumor samples of 912 women from the trial were
available for the present study, and tumor and treatment
characteristics of the patients are presented in Table 1.
The clinicopathological characteristics in this subset
were similar to those in thec o m p l e t es e r i e so f1 , 7 8 0
patients in the trial, such as tumor size ≤20 mm (79%
vs. 81%), positive ER status (78% vs. 80%), and tamoxi-
fen treatment (52% vs. 50%). The standard procedure
for tissue collection was fixation in 4% phosphate-buf-
fered formalin. Follow-up data were collected from
regional population registers and the Swedish Cause of
Death Registry. The mean follow-up period for patients
in the present investigation was 17 years.
The study was approved by the local ethical commit-
tee at the Karolinska University Hospital. According to
the approval, informed consent from the patients was
not required.
Hormone receptor status
The status of the ER and the progesterone receptor (PR)
was assessed retrospectively with immunohistochemistry
using the Ventana® automated slide stainer (Ventana
Medical Systems, S.A., Illkirch, France). Primary mono-
clonal antibodies were the CONFIRM™ mouse anti-ER
antibody (clone 6F11) and the CONFIRM™ mouse anti-
PR antibody (clone 16) from Ventana Medical Systems.
The cut-off level was set to 10% positively stained
tumor cell nuclei. In cases where immunohistochemical
data for ER were missing (13%), the ER status deter-
mined in clinical routine practice [14] was used with a
cut-off level of 0.10 fmol/μg DNA.
Tissue microarray and immunostaining of HOXB13
Formalin-fixed and paraffin-embedded tissue blocks
were selected as donor blocks for tissue microarray. Sec-
tions were cut from each donor block and were stained
with hematoxylin and eosin. Three morphologically
representative regions were chosen in each of the 912
tumor samples. Triplicate core tissue samples with a
diameter of 0.8 mm were taken from selected areas of
the tumors with a manual arrayer instrument (Beecher
Instruments, Inc, Sun Prairie, WI, USA), and were
arrayed into a paraffin block. Samples from human liver
were included on each tissue block for orientation
purpose.
Sections (4 μmt h i c k )f r o mt h et i s s u em i c r o a r r a y
blocks were cut and mounted onto frost-coated glass
slides, deparaffinized in xylene and rehydrated through a
graded alcohol series to distilled water. The slides were
Table 1 Patient characteristics
Patients in
present study
(n = 912)
Patients with HOXB13
expression data
(n = 866)
Original
cohort
(n = 1,780)
Tumor diameter
≤20 mm 697 (79) 661 (79) 1,393 (81)
>20 mm 189 (21) 181 (21) 323 (19)
Unavailable 26 24 64
Estrogen receptor status
Positive 686 (78) 651 (77) 1,183 (80)
Negative 198 (22) 190 (23) 296 (20)
Unavailable 28 25 301
Progesterone receptor status
Positive 415 (52) 401 (52) 590 (48)
Negative 380 (48) 366 (48) 627 (52)
Unavailable 117 99 563
Tamoxifen treatment
Yes 473 (52) 447 (52) 886 (50)
No 439 (48) 419 (48) 894 (50)
Data presented as number of patients (%). Tumor and treatment
characteristics of the patients included in the original cohort, patients in the
present study and patients in the present study with successful HOXB13
protein expression scoring.
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sure cooker for 3 minutes. After cooling to room tem-
perature, the slides were washed and incubated for
5 minutes in 3% hydrogen peroxide and methanol, and
were then incubated with serum-free protein block
(Dako Sweden AB, Stockholm, Sweden). A mouse
monoclonal antibody raised against amino acids 1 to
284 of human HOXB13 (F-9 sc-28333, lot number
L1504; Santa Cruz Biotechnology, Inc., Heidelberg, Ger-
many) was applied as primary antibody at a 1:50 dilu-
tion, and the slides were incubated at 4°C for 16 hours.
As the secondary reagent, the EnVision™ +D u a lL i n k
System labeled with horseradish peroxidase (Dako Swe-
den AB) for 30 min at room temperature was used. The
slides were incubated with 3,3’-diaminobenzidine tetra-
hydrochloride solution, counterstained with hematoxy-
lin, and mounted. BT-474 cells were used as a positive
control. All washing steps were performed in phos-
phate-buffered saline with 0.5% bovine serum albumin.
Evaluation of immunohistochemical staining
The stained tumor sections were evaluated indepen-
dently by two investigators (P-LJ and OS) without
knowledge about the clinicopathological data. The slides
were examined using a Leica LB30T microscope (Leica
Microsystems, Wetzlar, Germany) and were photo-
graphed using an Olympus SC20 digital camera (Olym-
pus Europe GmbH, Hamburg, Germany). Nuclear
staining intensity was graded as negative, weak, moder-
ate or strong. In cases with different scoring results, a
consensus score was reached after re-evaluation. In the
survival analysis, weak or no staining was categorized as
low expression and moderate to strong staining was
considered high expression.
Immunohistochemical analysis of HER2
Formalin-fixed, paraffin-embedded tissue was stained for
human epidermal growth factor receptor 2 (HER2) with
the DAKO AO0485 polyclonal rabbit antibody accord-
ing to the guidelines provided by the manufacturer. The
slides were scored as follows: 0 = no staining or <10%
of the cells positive for membrane staining; 1 = weak or
barely perceptible staining in >10% of the cells, staining
in only part of the cell membrane; 2 = weak to moder-
ate staining in the whole membrane in >10% of the
cells; and 3 = strong staining in the whole membrane
displayed by >10% of the cells. In all cases, the scoring
was limited to the invasive tumor.
Western blot
Lysates from the cell lines BT-474, SKBR3 and T47 D
were used to determine the specificity of the HOXB13
antibody. Real-time PCR analysis of HOXB13 mRNA
shows that SKBR3 and T47 D express very low, if any,
levels of HOXB13, whereas BT-474 cells show high
expression (unpublished data). The lysates were loaded
on a 4 to 15% gradient precast gel (Criterion; Bio-Rad
Laboratories AB, Sundbyberg, Sweden) and the proteins
were then transferred to a polyvinylidene fluoride mem-
brane. The membrane was incubated overnight with the
antibody (1:750) or with antibody previously incubated
with full-length recombinant HOXB13 protein in a 10-
fold excess. Antibodies were detected with a commercial
Enhanced Chemiluminescence Plus kit (GE Healthcare
UK Ltd, Little Chalfont, UK). To control for equal load-
ing, the membrane was stripped and then incubated
with a rabbit monoclonal GAPDH antibody (1:1,000;
Cell Signaling Technology, Inc., Danvers, MA, USA) and
a secondary polyclonal goat-anti-rabbit antibody
(1:2,000; Dako).
Statistical analysis
Survival curves were produced according to the life-
table method described by Kaplan and Meier, and differ-
ences in survival were estimated with the log-rank test.
Distant recurrence-free survival (DRFS) was defined as
the time from diagnosis to distant recurrence or to
death due to breast cancer. Breast cancer survival (BCS)
was the time elapsed from diagnosis to the date of death
related to breast cancer.
P values for relationships between HOXB13 and other
variables were assessed with a chi-square test for trend.
Univariate analyses of recurrence rates were performed
with Cox proportional hazard regression. Tests of inter-
actions between treatment effect and HOXB13 analysis
were performed by including product terms in the mod-
els, as well as other prognostic factors (tumor size and
HER2). All statistical procedures are comprised in the
statistical package Statistica 9.1 (StatSoft Scandinavia
AB, Uppsala, Sweden).
Results
HOXB13 protein expression
Immunohistochemical staining of HOXB13 was per-
formed on tissue microarray slides comprising a total of
912 tumors from breast cancer patients. The flow of
patients through the study is described in Figure 1. Grad-
ing of the protein expression was successful in 866 cases
(95% of the total number of patients), of which 291
(33.6%) displayed negative staining, 317 (36.6%) weak
staining, 212 (24.4%) moderate staining, and 46 (5.3%)
strong staining. Expression of HOXB13 was located
exclusively in the nuclei of the tumor cells. Examples of
the different levels of immunostaining are shown in Fig-
ure 2a to 2c. Western blot analysis of the specificity of
the antibody gave a single specific band at 34 kDa, which
was not detectable when the antibody was pre-incubated
with recombinant HOXB13 protein (Figure 2d).
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prediction of treatment outcome
Among the patients included in the present study, there
were 419 patients with HOXB13 protein expression data
who did not receive any adjuvant endocrine treatment -
74% of which had ER-positive disease (n = 310, 16
patients had unknown ER status). For all of the endo-
crine-untreated patients, irrespective of ER status,
neither the rate of distant recurrence nor the breast can-
cer-related survival differed between patients with differ-
ent levels of HOXB13 protein expression in the tumor.
Hazard ratios according to univariate Cox proportional
hazard modeling for patients presenting high expression
compared with patients presenting low expression were
not statistically significant (DRFS hazard ratio = 0.89,
95% confidence interval = 0.58 to 1.36, P =0 . 5 9 ;B C S
hazard ratio = 0.76, 95% confidence interval = 0.46 to
1.25, P = 0.28). Restricting the analysis to the ER-posi-
tive group gave similar results (DRFS hazard ratio =
0.78, 95% confidence interval = 0.47 to 1.29, P =0 . 3 2 ;
BCS hazard ratio = 0.60, 95% confidence interval = 0.32
to 1.14, P = 0.11).
Tamoxifen significantly increased the DRFS (P =
0.00002) and the BCS (P = 0.00008) in patients with
ER-positive tumors expressing none or low levels of
HOXB13 (Figure 3a,b), whereas the patients with a
moderate to high HOXB13 expression in their tumors
did not benefit from the endocrine treatment (Figure 3c,
d). The interaction between HOXB13 expression and
treatment effect was statistically significant for DRFS
(P = 0.035; multivariate model adjusted for tumor size
and HER2 status). Cox proportional hazard regressions
for the tamoxifen benefit in the different patient groups
are shown in Table 2.
For patients with tumors positive for both ER and PR,
survival analysis indicated that there was a significant
benefit from tamoxifen if the HOXB13 expression was
low (DRFS, P = 0.00001; BCS, P = 0.00004) (Figure 4a,
b). High levels of HOXB13 were still unfavorable for the
patients; no difference in relapse-free survival was noted
comparing the treated and untreated groups of patients
(DRFS, P =0 . 3 8 ;B C S ,P = 0.74) (Figure 4c,d). P values
for the multivariate interaction analyses, however, did
not reach statistical significance (P =0 . 0 7 2a n dP =
0.059 for DRFS and BCS, respectively; Table 2). Further
analyses showed that patients with ER-positive but PR-
negative tumors did not seem to benefit from tamoxifen,
regardless of HOXB13 expression levels (Table 2).
Correlation with prognostic factors
Analysis of possible relationships between HOXB13 pro-
tein expression and different tumor variables revealed
correlations to HER2, ER and tumor size (Table 3).
HOXB13 was inversely correlated to tumor size (P =
0.0048) and positively correlated to ER (P = 0.0022) and
HER2 levels (P = 0.0023).
Discussion
The results from studies aiming to find molecular mar-
kers to predict treatment response in breast cancer
demonstrate the importance of sensitive markers for
optimizing and individualizing breast cancer therapy
[1-4]. Several studies have reported an association
between HOXB13 mRNA expression and clinical out-
come [5-9,12]. In the present study, 34% of the tumors
were negative for HOXB13 protein expression - which
correlates well to the proportion of tumors with unde-
tectable mRNA expression in the study by Jansen and
colleagues [7].
The present report is the first about HOXB13 protein
expression and its potential as a predictor of response
to endocrine treatment. In the systemically untreated
group, HOXB13 could not predict the clinical outcome.
This is in line with our previous findings, examining
potential prognostic features of mRNA expression [8].
The clinical value of HOXB13 seems to be within its
Figure 1 Study design. Randomization and flow of patients
included in the original study and in the present study.
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protein results in less benefit from endocrine treatment
with tamoxifen. Most of the previous studies of
HOXB13 have included mainly lymph node-negative
patients, but we have previously shown that the predic-
tive feature of the two-gene ratio HOXB13:IL17BR is
also applicable to patients with nodal involvement [8].
Since the present study comprises a cohort of only
lymph node-negative patients, it would be interesting to
examine the HOXB13 protein expression in patients
with nodal involvement.
The causes of a high HOXB13 expression in breast
tumors are still not completely clear. The gene encoding
HOXB13 maps to chromosome 17q21, a region known
to be amplified in breast cancer. The gene encoding
HER2 also maps to this chromosomal location, which
raises the question about a possible coamplification of
the two genes. This is one potential reason for the posi-
tive correlation between the protein expressions we have
seen in the present study, a result that is in line with a
previous study by Wang and colleagues [12]. In that
study, however, HOXB13 displayed an ER-dependent
correlation with HER2 status, since the correlation was
evident only in ER-positive tumors. In our study, this
relationship was evident in both ER-positive tumors as
well as ER-negative tumors.
The correlation analysis of HOXB13 protein expression
and other proteins in the present study revealed a positive
correlation to ER; however, mRNA levels of HOXB13 have
been reported to correlate negatively with ER [7,12]. There
is also evidence pointing towards HOXB13 being an ER-
responsive gene, with estradiol treatment resulting in a
suppression of the gene [11,12]. Given that the intrinsic
levels of estradiol are highly variable between different
breast tumors [15,16] and that HOXB13 may be a coacti-
vating factor in ER signaling [17], one may speculate that
high HOXB13 protein levels can contribute to increased
ER activity despite a low estradiol concentration within
the tumor. A decreased estradiol concentration can result
from a lower intrinsic production, or can occur during
treatment with aromatase inhibitors. In fact, it seems
HOXB13 is not only a predictor of tamoxifen resistance,
but is a marker of resistance to endocrine therapy per se.
In a recent study by Ma and colleagues, HOXB13 gene
expression was shown to predict benefit from treatment
with the aromatase inhibitor letrozole [18]. In the future, a
Figure 2 HOXB13 grading and antibody control. Tumor tissue immunostained for HOXB13: (a) weak, (b) moderate and (c) strong. (d)
Western blot analysis of HOXB13 in protein lysates from SKBR3 cells, T47 D cells and BT-474 cells. Lane BT-474*, antibody was preincubated with
recombinant HOXB13 protein prior to incubation with the membrane.
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Page 5 of 8Figure 3 Cumulative survival for patients with estrogen receptor-positive tumors, stratified by HOXB13. Kaplan-Meier curves illustrating
clinical outcome in terms of distant recurrence-free survival and breast cancer survival for patients with estrogen receptor (ER)-positive tumors
undergoing tamoxifen treatment or no endocrine therapy: (a), (b) low or no HOXB13 expression; (c), (d) moderate or high HOXB13 expression.
Table 2 Estimation of the benefit from adjuvant tamoxifen treatment
Tumor status Tamoxifen treatment versus no endocrine treatment
Distant recurrence Breast cancer death
Hazard ratio (95% CI) P value Pinteraction* Hazard ratio (95% CI) P value Pinteraction*
ER-positive
Low HOXB13 expression 0.38 (0.23 to 0.60) 0.000048 0.35 (0.20 to 0.60) 0.00016
High HOXB13 expression 0.88 (0.47 to 1.65) 0.69 0.035 0.84 (0.37 to 1.90) 0.67 0.060
ER-positive, PR-positive
Low HOXB13 expression 0.26 (0.14 to 0.49) 0.000022 0.24 (0.11 to 0.50) 0.00015
High HOXB13 expression 0.70 (0.31 to 1.56) 0.38 0.072 0.82 (0.27 to 2.56) 0.74 0.059
ER-positive, PR-negative
Low HOXB13 expression 0.69 (0.31 to 1.56) 0.37 0.64 (0.26 to 1.56) 0.33
High HOXB13 expression 0.89 (0.31 to 2.54) 0.83 0.51 0.60 (0.17 to 2.13) 0.43 0.98
Cox regression analysis of distant recurrence rate and breast cancer-related deaths for patients with estrogen receptor (ER)-positive tumors, ER-positive and
progesterone receptor (PR)-positive tumors, and ER-positive and PR-negative tumors in relation to HOXB13 protein expression. CI, confidence interval. *Tests
whether there is a difference in the treatment response. The models included treatment (tamoxifen vs. no endocrine treatment), HOXB13 expression (high vs.
low), an interaction variable, tumor size (>20 mm vs. ≤20 mm) and HER2 status (3+ vs. 0 to 2+).
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Page 6 of 8study including both HOXB13, ER and estradiol concen-
trations in a set of tumors would be welcome.
The mechanistic effects of HOXB13 in breast cancer
are being investigated, but there are few studies pub-
lished in this matter. The two-gene ratio HOXB13:
IL17BR has been proposed as a marker for impaired ER
gene regulation [12]. The presence of PR in a tumor is
the most commonly used indicator of functional ER sig-
naling [19]; patients with tumors expressing both ER
and PR benefit most from tamoxifen therapy. The worse
p r o g n o s i sw h e nH O X B 1 3i sh i g h ,w h i c hi ss e e ni no u r
study, shows that HOXB13 in fact has a predictive value
in addition to PR.
Conclusions
The present study is the first about HOXB13 protein
expression in breast cancer. We have shown that
HOXB13 is predictive of response to adjuvant tamoxifen
therapy, in terms of a longer DRFS and BCS for tamoxi-
fen-treated breast cancer patients if the protein expres-
sion is low or absent. Nevertheless, further studies are
needed to verify our results.
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Table 3 Correlation between HOXB13 protein levels and
prognostic factors analyzed with the chi-square test for
trend
HOXB13 expression P value
Negative Low Intermediate High
Tumor size
≤20 mm 205 (31.0) 249 (37.7) 168 (25.4) 39 (5.9)
>20 mm 78 (43.1) 59 (32.6) 37 (20.4) 7 (3.9 0.0048
Human epidermal growth factor receptor 2
0 189 (38.4) 172 (35.0) 102 (20.7) 29 (5.9)
1+ 38 (26.6) 55 (38.5) 45 (31.5) 5 (3.5)
2+ 16 (20.5) 32 (41.0) 26 (33.3) 4 (5.1)
3+ 27 (29.7) 30 (33.0) 27 (29.7) 7 (7.7) 0.0023
Estrogen receptor*
0 63 (39.4) 48 (30.0) 34 (21.3) 15 (9.4)
1 to 24 5 (35.7) 5 (35.7) 4 (28.6) 0 (0)
25 to 74 69 (57.0) 35 (28.9) 16 (13.2) 1 (0.8)
75 to 89 63 (33.3) 67 (35.5) 47 (24.9) 12 (6.4)
>90 62 (22.1) 110 (39.3) 96 (34.3) 12 (4.3) 0.0022
Progesterone receptor*
0 120 (39.9) 92 (30.6) 68 (22.6) 21 (7.0)
1 to 24 43 (42.6) 29 (28.7) 26 (25.7) 3 (3.0)
25 to 74 58 (29.3) 87 (43.9) 48 (24.2) 5 (2.5)
75 to 89 27 (24.1) 42 (37.5) 33 (29.5) 10 (8.9)
>90 20 (36.4) 21 (38.2) 12 (21.8) 2 (3.6) 0.13
Data presented as number of patients (%).*Percentage of positive nuclei
stained with immunohistochemistry.
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